Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
L.V. Gubareva, L. Kaiser, F.G. Hayden.
Influenza virus neuraminidase inhibitors.
Lancet, 355 (2000), pp. 827-835
[3.]
R.R. Grunert, J.W. McGahen, W.L. Davies.
The in vivo antiviral activity of 1-adamantanamine (amantadine). I. Prophylactic and therapeutic activity against influenza viruses.
Virology, 26 (1965), pp. 262-269
[4.]
J.M. Colacino, K.A. Staschke, W.G. Laver.
Approaches and strategies for the treatment of influenza virus infections.
Antivir Chem Chemother, 10 (1999), pp. 155-185
[5.]
Centers for Disease Control and Prevention.
Antiviral agents for influenza: background information for clinicians; 2003 December 16,
[6.]
American Academy of Pediatrics.
Influenza.
Red Book: 2003 Report of the Committee on Infectious Diseases, 26th ed, pp. 382-391
[7.]
Centers for Disease Control and Prevention.
Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Mmwr Morb Mortal Wkly Rep, 52 (2003), pp. 1-36
[8.]
CDC.
Neuraminidase inhibitors for treatment of influenza A and B infections.
Mmwr Morb Mortal Wkly Rep, 48 (1999), pp. 1-9
[9.]
T. Jefferson, V. Demicheli, J. Deeks, D. Rivetti.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults (Cochrane Review).
The Cochrane Library, Issue 1,
[10.]
N.J. Matheson, M. Symmonds-Abrahams, A. Sheikh, S. Shepperd, A. Harnden.
Neuraminidase inhibitors for preventing and treating influenza in children.
The Cochrane Database of Systematic Reviews, 3 (2003), pp. CD:00274
[11.]
N.J. Cooper, A.J. Sutton, K.R. Abrams, A. Wailoo, D.A. Turner, K.G. Nicholson.
Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomized controlled trials.
Bmj, 326 (2003), pp. 1-7
[12.]
group MIST study.
Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections.
Lancet, 352 (1998), pp. 1877-1881
[13.]
F.G. Hayden, et al.
Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections.
N Engl J Med, 337 (1997), pp. 874-880
[14.]
L. Kaiser, C. Wat, T. Mills, P. Mahoney, P. Ward, F. Hayden.
Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.
Arch Intern Med, 163 (2003), pp. 1667-1672
[15.]
F.G. Hayden, L.V. Gubareva, A.S. Monto, T.C. Klein, M.J. Elliot, et al.
Zanamivir Family Study Group. Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group.
N Engl J Med, 343 (2000), pp. 1282-1289
[16.]
T.O. Jefferson, V. Demicheli, J.J. Deeks, D. Rivetti.
Amantadine and rimantadine for preventing and treating influenza A in adults (Cochrane Review).
The Cochrane Library, Issue 1,
[17.]
T.M. Uyeki.
Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza.
Pediatr Infect Dis J, 22 (2003), pp. 164-177
[18.]
K. Shiraishi, K. Mitamura, Y. Sakai-Tagawa, H. Goto, N. Sugaya, Y. Kawaoka.
High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza.
J Infect Dis, 188 (2003), pp. 57-61
[19.]
D.M. Fleming.
Managing influenza: amantadine, rimantadine and beyond.
Int J Clin Pract, 55 (2001), pp. 189-195
[20.]
Centers for Disease Control and Prevention.
Guidelines & Recommendations.
Influenza antiviral medications: interim chemoprophylaxis and treatment guidelines; 2003, December 17,
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados